Durvalumab induces an NK cell response associated with clinical benefit of patients with advanced NSCLC

Category Primary study
JournalCancer Research
Year 2019
This article has no abstract
Epistemonikos ID: 8164eef860bcc255daf1174ec6b9f7296a8a8b86
First added on: Feb 11, 2025